Source: MarketWatch ↗
Novartis’s failed trial for cholesterol drug leads to broad biopharma stock selloff
|
Translation unavailable. Please try again.
What the source reports
Along with several other drugmakers, Novartis has bet that lowering Lp(a) will cut the risk of sometimes fatal cardiovascular events.
Read the original report on MarketWatch ↗